 ROCKVILLE, MD, Jan. 25, 2021 GLOBE NEWSWIRE -- MacroGenics, Inc. Nasdaq: MGNX, a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of results from the SOPHIA trial of MARGENZATM margetuximab-cmkb in the Journal of the American Medical Association JAMA Oncology. SOPHIA is a pivotal Phase 3 clinical trial of 536 adult patients with metastatic HER2-positive breast cancer previously treated with two or more anti-HER2 regimens and from one to three lines of therapy for metastatic disease. In the study, MARGENZA demonstrated a statistically significant 24 reduction in the risk of disease progression or death compared to Herceptin, each in combination with chemotherapy Hazard Ratio HR 0.76; 95 CI, 0.59-0.98; p0.03; median PFS 5.8 vs. 4.9 months. 